Edition:
United Kingdom

Portola Pharmaceuticals Inc (PTLA.OQ)

PTLA.OQ on NASDAQ Stock Exchange Global Select Market

25.58USD
16 Aug 2018
Change (% chg)

$0.41 (+1.63%)
Prev Close
$25.17
Open
$25.28
Day's High
$26.03
Day's Low
$24.63
Volume
691,932
Avg. Vol
427,284
52-wk High
$64.00
52-wk Low
$24.63

Select another date:

Thu, May 24 2018

BRIEF-Portola Pharmaceuticals Receives $100 Mln Milestone Payment From Healthcare Royalty Partners For FDA Approval Of Andexxa

* PORTOLA PHARMACEUTICALS RECEIVES $100 MILLION MILESTONE PAYMENT FROM HEALTHCARE ROYALTY PARTNERS FOR FDA APPROVAL OF ANDEXXA® Source text for Eikon: Further company coverage:

BRIEF-Portola Pharmaceuticals Q1 Loss Per Share $1.28

* PORTOLA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-U.S. FDA Approves Portola Pharmaceuticals’ Andexxa

* U.S. FDA APPROVES PORTOLA PHARMACEUTICALS’ ANDEXXA®, FIRST AND ONLY ANTIDOTE FOR THE REVERSAL OF FACTOR XA INHIBITORS

BRIEF-Portola Pharmaceuticals Plans To Appeal Negative CHMP Opinion For Betrixaban In The European Union

* PORTOLA PHARMACEUTICALS RECEIVES AND PLANS TO APPEAL NEGATIVE CHMP OPINION REGARDING MARKETING AUTHORIZATION FOR BETRIXABAN IN THE EUROPEAN UNION

EMA panel recommends against Portola's clot prevention drug

A panel of European Medicines Agency on Friday recommended against granting marketing approval to Portola Pharmaceuticals Inc's oral blood thinner, saying the benefits of the drug did not outweigh risks.

EMA panel recommends against Portola's clot prevention drug

March 23 A panel of European Medicines Agency on Friday recommended against granting marketing approval to Portola Pharmaceuticals Inc's oral blood thinner, saying the benefits of the drug did not outweigh risks.

BRIEF-EMA Panel Recommends Against Approval Of Portola Drug For Preventing Blood Clots Betrixiban

* EU MEDICINES AGENCY RECOMMENDS AGAINST APPROVAL OF PORTOLA PHARMACEUTICALS' DRUG FOR PREVENTING BLOOD CLOTS BETRIXIBAN Source text (http://bit.ly/2pBz519) Further company coverage:

BRIEF-Portola Pharmaceuticals Announces New Interim Results From Ongoing Annexa-4 Study

* PORTOLA PHARMACEUTICALS ANNOUNCES NEW INTERIM RESULTS FROM ONGOING ANNEXA-4 STUDY OF FACTOR XA INHIBITOR REVERSAL AGENT ANDEXXA® (ANDEXANET ALFA) IN PATIENTS WITH LIFE-THREATENING BLEEDING

BRIEF-Portola Pharmaceuticals Q4 Loss Per Share $1.41

* PORTOLA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Select another date: